Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANOQ NASDAQ:GELS NASDAQ:INM NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANOQCano Health$0.24$0.24$0.10▼$174.00$1.30MN/AN/AN/AGELSGelteq$0.49-2.4%$0.58$0.39▼$3.51$5.32M-0.19186,573 shs4,302 shsINMInMed Pharmaceuticals$1.54-2.5%$0.97$0.58▼$5.50$5.24M0.975.05 million shs147,444 shsRDHLRedhill Biopharma$1.02-1.0%$0.93$0.71▼$3.31$5.35M4.98108,358 shs128,829 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANOQCano Health0.00%0.00%0.00%0.00%0.00%GELSGelteq0.00%+1.64%+5.52%-36.28%-70.59%INMInMed Pharmaceuticals0.00%+0.64%+143.08%+78.39%-44.95%RDHLRedhill Biopharma0.00%+3.00%+3.00%+11.46%-48.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANOQCano Health$0.24$0.24$0.10▼$174.00$1.30MN/AN/AN/AGELSGelteq$0.49-2.4%$0.58$0.39▼$3.51$5.32M-0.19186,573 shs4,302 shsINMInMed Pharmaceuticals$1.54-2.5%$0.97$0.58▼$5.50$5.24M0.975.05 million shs147,444 shsRDHLRedhill Biopharma$1.02-1.0%$0.93$0.71▼$3.31$5.35M4.98108,358 shs128,829 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANOQCano Health0.00%0.00%0.00%0.00%0.00%GELSGelteq0.00%+1.64%+5.52%-36.28%-70.59%INMInMed Pharmaceuticals0.00%+0.64%+143.08%+78.39%-44.95%RDHLRedhill Biopharma0.00%+3.00%+3.00%+11.46%-48.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANOQCano Health 0.00N/AN/AN/AGELSGelteq 1.00SellN/AN/AINMInMed Pharmaceuticals 1.00SellN/AN/ARDHLRedhill Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CANOQ, GELS, RDHL, and INM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANOQCano Health$3.14B0.00N/AN/A($99.38) per share0.00GELSGelteq$110K47.22N/AN/A$1.08 per share0.45INMInMed Pharmaceuticals$4.94M1.03N/AN/A$6.71 per share0.23RDHLRedhill Biopharma$290K18.25N/AN/A$0.83 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANOQCano Health-$594.42MN/AN/AN/AN/AN/AN/AN/AN/AGELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/AINMInMed Pharmaceuticals-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%N/ARDHLRedhill Biopharma-$430K$1,046.750.00N/AN/AN/AN/AN/A8/20/2026 (Estimated)Latest CANOQ, GELS, RDHL, and INM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q3 2026INMInMed Pharmaceuticals-$94.4436-$0.69+$93.7536-$0.73$1.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCANOQCano HealthN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANOQCano HealthN/AN/AN/AGELSGelteqN/AN/AN/AINMInMed PharmaceuticalsN/A3.123.12RDHLRedhill BiopharmaN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANOQCano Health37.97%GELSGelteqN/AINMInMed Pharmaceuticals20.12%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipCANOQCano Health13.93%GELSGelteqN/AINMInMed Pharmaceuticals0.85%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANOQCano Health2,7005.41 million4.66 millionN/AGELSGelteqN/A10.71 millionN/AN/AINMInMed Pharmaceuticals103.31 million3.29 millionNot OptionableRDHLRedhill Biopharma2105.19 million4.84 millionNo DataCANOQ, GELS, RDHL, and INM HeadlinesRecent News About These CompaniesRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against KukboJune 8 at 7:00 AM | prnewswire.comRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsJune 2, 2026 | prnewswire.comBessor Announces Entering Option for the Redhill PropertyMay 26, 2026 | globenewswire.comRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseApril 30, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...April 23, 2026 | finanznachrichten.deRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026April 22, 2026 | prnewswire.comJoint U.S. Commercialization of RedHill's Talicia® CommencesFebruary 25, 2026 | prnewswire.comRedhill Biopharma stock soars on GLP-1 side effect treatment progressJanuary 5, 2026 | investing.comRedHill Biopharma shares jump on progress toward treating GLP-1 side effectsJanuary 5, 2026 | msn.comRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsJanuary 5, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | finanznachrichten.deRedHill Biopharma announces in vivo results on opaganib, venetoclaxDecember 15, 2025 | msn.comRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | prnewswire.comRedHill Biopharma regains compliance with Nasdaq equity requirementDecember 1, 2025 | msn.comRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity RequirementDecember 1, 2025 | prnewswire.comRedHill Biopharma announces $10.5M New York Supreme Court judgment winNovember 4, 2025 | msn.comRedhill Biopharma stock jumps after court win against KukboNovember 4, 2025 | za.investing.comRedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for EnforcementNovember 4, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANOQ, GELS, RDHL, and INM Company DescriptionsCano Health NYSE:CANOQCano Health, Inc. provides primary care medical services to its members in Florida, the United States. It offers health care plans for seniors through Medicare Advantage program that allows members to get access to its affiliated medical centers providers and physicians to set appointments, and administers integrated virtual care, wellness services, ancillary services, such as physiotherapy, home services, transportation, telemedicine, and a 24/7 urgency line without any additional costs. The company operates pharmacies, as well as provides dental and pharmacy delivery services. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida. On February 4, 2024, Cano Health, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Gelteq NASDAQ:GELS$0.48 -0.01 (-2.41%) Closing price 03:07 PM EasternExtended Trading$0.49 +0.01 (+1.03%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.InMed Pharmaceuticals NASDAQ:INM$1.54 -0.04 (-2.53%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.26%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Redhill Biopharma NASDAQ:RDHL$1.02 -0.01 (-0.97%) Closing price 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.59%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
